BioWorld

Oct. 31, 2003

View Archived Issues

IPO Trifecta: CancerVax, Genitope Myogen All Price Public Offerings

A trio of biotech IPOs priced in succession, but the public money appears to be flowing conservatively, some industry observers think. (BioWorld Today) Read More

Alkermes' Risperidone Wins FDA Nod For Schizophrenia

Read More

Now With Full Rights, Chiron Plans Tifacogin CAP Phase III

Read More

Aphton's Phase III Positive For G17DT Cancer Vaccine

Read More

Other News To Note

Read More